Edgewise Therapeutics Inc. Common Stock vs Rex Fang & Innovation Equity Premium Income ETF — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.11 (market cap $3.94B), while Rex Fang & Innovation Equity Premium Income ETF trades at $41.84 (market cap $744.46M). The key difference: Edgewise Therapeutics Inc. Common Stock is far larger — about 5.3× Rex Fang & Innovation Equity Premium Income ETF's market cap, and Edgewise Therapeutics Inc. Common Stock is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and Rex Fang & Innovation Equity Premium Income ETF for 57 Days on average.
| EWTX | FEPI | |
|---|---|---|
Market Cap | $3.94B | $744.46M |
Volume | 810,104 | 116,338 |
Sector | Health | Income / Options Overlay |
52-Week High | $48.35 | $49.54 |
52-Week Low | $14.89 | $37.98 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $3.48B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $43.28, showing minimal daily movement with a 0.14% gain. The ETF employs a covered call strategy on AI and mega-cap tech stocks, generating substantial weekly dividends averaging $0.20-0.21 per share. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. Recent news highlights FEPI's 25% yield but notes underperformance compared to peers in total returns.
FEPI offers high income potential through its covered call strategy but faces capped upside and concentrated tech exposure risks. The ETF's performance depends heavily on AI sector volatility and options pricing efficiency. While attractive for income-focused investors, total return potential may lag broader market indices during strong bull markets.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →